Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2018.03.014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparative Effectiveness of Early-Line Nab-Paclitaxel vs. Paclitaxel in Patients With Metastatic Breast Cancer: A US Community-Based Real-World Analysis

Cancer Management and Research
Oncology
2018English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Oncotarget
Oncology
2017English

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With Nab-Paclitaxel and Gemcitabine

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2017English

Nab-Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer With Visceral Crisis: Evaluation of Efficacy and Tolerability in Clinical Practice

Medical Council
2019English

Paclitaxel in Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
1998English

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Comparative Effectiveness of Nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

Advances in Therapy
MedicinePharmacology
2018English

Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer

Cancer Management and Research
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy